Terminology for antithrombotic therapy regimens and indications in venous and arterial thrombosis
| Term . | Definition . | Common applications . |
|---|---|---|
| Antithrombotic therapy regimens | ||
| Dual antiplatelet therapy | Low dose aspirin + P2Y12 inhibitor∗ | Any arterial thrombosis |
| Dual antithrombotic therapy | Anticoagulation + 1 antiplatelet agent | Atrial fibrillation + CAD |
| Dual pathway inhibition | Low dose anticoagulation (rivaroxaban 2.5 mg daily) + antiplatelet agent(s) | Stable CAD PAD after revascularization |
| Triple antithrombotic therapy | Anticoagulation + 2 antiplatelet agents | Atrial fibrillation + CAD |
| Triple therapy | ||
| Indications for antithrombotic therapy | ||
| Prevention of stent thrombosis84 | CAD, PAD | |
| Early | 0-30 d after stent implantation | |
| Late | >30 d to 1 y after stent implantation | |
| Very late | >1 y after stent implantation | |
| Initiation phase | Initial provision of anticoagulants after VTE diagnosis (7 d for apixaban; 21 d for rivaroxaban)35 | VTE |
| Treatment phase | Period after initiation to complete treatment for acute VTE (3 mo)35 | |
| Extended phase | Period of anticoagulant at full or reduced dose for secondary prevention (after 3 mo)35 | |
| Term . | Definition . | Common applications . |
|---|---|---|
| Antithrombotic therapy regimens | ||
| Dual antiplatelet therapy | Low dose aspirin + P2Y12 inhibitor∗ | Any arterial thrombosis |
| Dual antithrombotic therapy | Anticoagulation + 1 antiplatelet agent | Atrial fibrillation + CAD |
| Dual pathway inhibition | Low dose anticoagulation (rivaroxaban 2.5 mg daily) + antiplatelet agent(s) | Stable CAD PAD after revascularization |
| Triple antithrombotic therapy | Anticoagulation + 2 antiplatelet agents | Atrial fibrillation + CAD |
| Triple therapy | ||
| Indications for antithrombotic therapy | ||
| Prevention of stent thrombosis84 | CAD, PAD | |
| Early | 0-30 d after stent implantation | |
| Late | >30 d to 1 y after stent implantation | |
| Very late | >1 y after stent implantation | |
| Initiation phase | Initial provision of anticoagulants after VTE diagnosis (7 d for apixaban; 21 d for rivaroxaban)35 | VTE |
| Treatment phase | Period after initiation to complete treatment for acute VTE (3 mo)35 | |
| Extended phase | Period of anticoagulant at full or reduced dose for secondary prevention (after 3 mo)35 | |
CAD, coronary artery disease; PAD, peripheral artery disease.
P2Y12 inhibitors: clopidogrel, prasugrel, ticagrelor, and cangrelor.